The Zhitong Finance App learned that True Healthcare-B (02697) rose more than 41% this morning to a high of HK$62.6, with a turnover of HK$102 million.
According to the news, the “AI Empowering Medicine Clinical Application Exchange Conference and 'True Health' Health Industry Digital Intelligence Annual Conference” was held at the Zhangjiang Campus of Fudan University at the beginning of this month. At the meeting, Ding Xuan, director of the People's Hospital of Zheng'an County, Guizhou Province, explained that the hospital introduced real health care puncture and ablation surgery robots in 2025, and has now helped nearly 100 patients receive robot-assisted puncture diagnosis and treatment. In response to problems such as traditional manual puncture reliance on doctors' experience and difficulties in locating small lesions, relevant equipment supports hospitals in carrying out standardized minimally invasive diagnosis and treatment to help patients obtain accurate diagnosis and treatment services nearby.
True Health Medical's core products are percutaneous surgical robots, including TH-S1, TH-S, TH-S Pro, and TH-SA models. They have all obtained three types of registration certificates from the State Drug Administration and approved for lung and abdominal puncture. In addition to this, the company's in vitro organ support platform centered on room temperature organ perfusion is also being promoted simultaneously. In September of this year, the company signed a sales contract with an independent third party to sell puncture navigation and positioning systems to the buyer. The total contract amount is close to RMB 100 million. The company's commercialization process is expected to continue to accelerate.